Osteonectin Antibody (High Specificity)

Description

Osteonectin Antibody (High Specificity)
Catalog number: B2010560
Lot number: Batch Dependent
Expiration Date: Batch dependent
Amount: 100 uL
Molecular Weight or Concentration: na
Supplied as: Serum
Applications: molecular tool in the study of Osteonectin (a component of the noncollagenous proteins of the bone extracellular matrix)
Storage: -20C
Keywords: Anti-Osteonectin Antibody
Grade: Biotechnology grade. All products are highly pure. All solutions are made with Type I ultrapure water (resistivity >18 MΩ-cm) and are filtered through 0.22 um.

References:
1: Rosset EM, Bradshaw AD. SPARC/osteonectin in mineralized tissue. Matrix Biol.
2016 May-Jul;52-54:78-87.

2: Motamed K. SPARC (osteonectin/BM-40). Int J Biochem Cell Biol. 1999
Dec;31(12):1363-6.

3: Duś-Ilnicka I, Radwan-Oczko M, Gerber H, Hałoń A. Histopathological
assessment of oral leukoplakia. Osteonectin as possible biomarker for further
diagnostics. Pol J Pathol. 2020;71(2):138-145.

4: Rossi MK, Gnanamony M, Gondi CS. The ‘SPARC’ of life: Analysis of the role of
osteonectin/SPARC in pancreatic cancer (Review). Int J Oncol. 2016
May;48(5):1765-71.

5: Ciceri P, Elli F, Cappelletti L, Tosi D, Savi F, Bulfamante G, Cozzolino M.
Osteonectin (SPARC) Expression in Vascular Calcification: In Vitro and Ex Vivo
Studies. Calcif Tissue Int. 2016 Nov;99(5):472-480.

6: Sage EH. Purification of SPARC/osteonectin. Curr Protoc Cell Biol. 2003
Feb;Chapter 10:Unit 10.11.

7: Sodek J, Zhu B, Huynh MH, Brown TJ, Ringuette M. Novel functions of the
matricellular proteins osteopontin and osteonectin/SPARC. Connect Tissue Res.
2002;43(2-3):308-19.

8: Amaral CB, Leite JDS, Fonseca ABM, Ferreira AMR. Vimentin, osteocalcin and
osteonectin expression in canine primary bone tumors: diagnostic and prognostic
implications. Mol Biol Rep. 2018 Oct;45(5):1289-1296.

9: Koblinski JE, Kaplan-Singer BR, VanOsdol SJ, Wu M, Engbring JA, Wang S,
Goldsmith CM, Piper JT, Vostal JG, Harms JF, Welch DR, Kleinman HK. Endogenous
osteonectin/SPARC/BM-40 expression inhibits MDA-MB-231 breast cancer cell
metastasis. Cancer Res. 2005 Aug 15;65(16):7370-7.
10: Delany AM, Kalajzic I, Bradshaw AD, Sage EH, Canalis E. Osteonectin-null
mutation compromises osteoblast formation, maturation, and survival.
Endocrinology. 2003 Jun;144(6):2588-96.

Products Related to Osteonectin Antibody (High Specificity): Antibodies